Sun Pharmaceutical
SUNPHARMA · NSE · Pharma · India
Financials at a glance
Source: Yahoo FinanceAnnual
Quarterly · last 5
Revenue (FY2026)
₹58,462 Cr
Net margin
19.6%
Revenue CAGR (3y)
+10.0%
Profit CAGR (3y)
+10.6%
Net profit (FY2026)
₹11,479 Cr
Ask MarketChacha about SUNPHARMA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Aug 31, 2026
Sun Pharmaceutical was the top Sensex gainer on a day the index fell about 0.4%, with pharma acting as a defensive on a risk-off session driven by Brent crude moving above $90 on US-Iran tensions. No company-specific announcement was reported.
source 1 ↗· confidence: medium - Aug 20, 2026
Sun Pharmaceutical closed at Rs 1,900 and ended at its day high, among the top five Nifty gainers in an otherwise negative session. Pharma was one of the few pockets of strength; no company-specific announcement was reported on the day.
- Aug 5, 2026
Sun Pharma declined with the pharma sector as investors stayed cautious over proposed US tariffs on imported generic medicines, the sector's largest export market.
source 1 ↗· confidence: medium
Daily moves with the verified reason behind them. Education only — not investment advice.
On MarketChacha
Posts about SUNPHARMA- Sun Pharma: what its new Moody's Baa1 / S&P BBB+ rating actually meansc/india-daily · 9/9/2026▲ 0
- Sun Pharma: what their latest filing actually meansc/india-daily · 9/1/2026▲ 0
- Sun Pharma: what their latest filing actually meansc/india-daily · 8/7/2026 · 1 comment▲ 1
- Sun Pharma: what their latest filing actually meansc/india-daily · 7/30/2026▲ 0
- Why is Dr Reddy's at a 52-week high — six green days and counting?c/indianmarkets · 6/29/2026▲ 0
- Sun Pharma's $11B Organon deal lights a fire under Nifty—pharma's back?c/indianmarkets · 4/27/2026▲ 1
Financials
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹58,462 Cr | ₹11,479 Cr | 19.6% |
| FY2025 | ₹52,578 Cr | ₹10,929 Cr | 20.8% |
| FY2024 | ₹48,497 Cr | ₹9,576 Cr | 19.7% |
| FY2023 | ₹43,886 Cr | ₹8,474 Cr | 19.3% |
Quarterly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| Q1 FY27 | ₹15,300 Cr | ₹2,895 Cr | 18.9% |
| Q4 FY26 | ₹14,612 Cr | ₹2,714 Cr | 18.6% |
| Q3 FY26 | ₹15,521 Cr | ₹3,369 Cr | 21.7% |
| Q2 FY26 | ₹14,478 Cr | ₹3,118 Cr | 21.5% |
| Q1 FY26 | ₹13,851 Cr | ₹2,279 Cr | 16.5% |
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
Intimation Under Regulation 30 Of SEBI LODR
As attached
BSE9/11/2026International Credit Ratings
BSE9/8/2026materialSun Pharma participates in White House Signing Ceremony highlighting U.S. Medicines Pricing and Access Commitments
BSE9/1/2026Filing of Application for Reclassification with Stock Exchanges
BSE8/13/2026Outcome of 21st Annual General Meeting of Sun Pharma Advanced Research Company Limited held on August 10, 2026
BSE8/10/2026materialReceipt Of No-Objection Letters From The Stock Exchanges For Reclassification Of Promoter Group
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group
BSE8/6/2026Q1FY27 Earnings Call Transcript
BSE8/6/2026Update on Credit Rating
BSE8/5/2026materialVoting Results And Scrutinizer Report Of 34Th AGM Held On 31 July 2026
Voting Results for 34th AGM
BSE7/31/2026Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of the 34th Annual General Meeting held on 31 July 2026
BSE7/31/2026materialQ1FY27-Investor Call Audio Recording
SPIL Q1FY27-Investor Call Audio Recording
BSE7/31/2026Conclusion Of The Board Meeting Held Today, I.E., 31 July 2026
Conclusion of the Board Meeting held today
BSE7/31/2026Sun Pharma receives approval to manufacture and market semaglutide in Brazil
BSE7/29/2026Intimation for Receipt of Request for Reclassification of Shareholder Category
BSE7/27/2026Sun Pharma notes Organon Shareholder approval for proposed acquisition
BSE7/24/2026Business Responsibility and Sustainability Report for FY 26
BSE7/16/2026Notice of 21st Annual General Meeting along with the Annual Report for FY 26
BSE7/16/2026materialSun Pharma Advanced Research Company Ltd - 532872 - Reg. 34 (1) Annual Report.
Annual Report 2025-26 and the Notice of 21st Annual General Meeting
BSE7/16/2026Press Release
BSE7/15/2026Notice of 34th Annual General Meeting along with the Annual Report for FY 2025-26
BSE7/6/2026materialAnnual Report 2025-26 and the Notice of 34th Annual General Meeting
BSE7/6/202621st Annual General Meeting of the Company
BSE7/6/2026materialIntimation regarding Change in Senior Management Team of the Company
BSE6/26/2026Termination of License Agreement with CMS Bridging DMCC
BSE6/25/2026Acquisition of Innovcare Lifesciences Private Limited
BSE6/20/2026material
In the news
- Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amountCNBC TV18 · 9/11/2026
- Sun Pharma may not announce any dividends, buybacks between FY27-29 - Bernstein explains whyCNBC TV18 · 9/11/2026
- Sun Pharmaceutical Industries Ltd drops for fifth straight sessionBusiness Standard · 9/9/2026
- Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata PowerBusiness Standard · 9/9/2026
- Stocks To Watch Today: Bajaj Finance, Tata Communications, PVR Inox, Avenue Super Marts, Bank of Baroda and Sun Pharma & MoreNDTV Profit · 9/9/2026
- Sun Pharma Advanced Research Company Ltd is Rated BuyMarketsMojo · 9/8/2026
- Sun Pharma Advanced Research Company share price: Good Buy Now?Univest · 9/7/2026
- Sun Pharma Advanced Research Company Ltd is Rated Strong SellMarketsMojo · 9/4/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.